Define clinical exposure associated with QTc liability

Data Card

Early cardiac derisking: A clinically translatable hiPSC cardiomyocyte assay

Achieve action potential recordings from intrinsically paced hiPSC-CMs with Metrion’s clinically predictive hiPSC cardiomyocyte assay.

Simultaneous high-resolution measurement across 96 well plate at 10,000 Hz
Recordings using voltage-sensitive dye equivalent in quality to patch clamp
Multiple endpoints evaluated (APD20/50/90, rise time, beat rate, triangulation)
Measurement of acute (30min) and chronic (24h/48h) effects
Predicts clinical exposure associated with 10ms QTc prolongation
Defines exposure associated with QRS probability
Highlights unknown acute/chronic toxicity

Contact us for a quote or discussion

Recommended Publications

Latest Publications

Webinar recording - Accelerating Pain Therapeutic Discovery: Nav1.9 as a Drug Target for Treatment of Pain

Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.

Development of a High-Throughput Automated Electrophysiology Assay for Human Nav1.9 Inhibitor Screening

Alex Haworth, Senior Scientist at Metrion, introduces a poster demonstrating Metrion's development of a monoclonal CHO cell line expressing hNav1.9, validated via manual and automated patch clamp techniques.

View All

Webinar recording - Accelerating Pain Therapeutic Discovery: Nav1.9 as a Drug Target for Treatment of Pain

Development of a High-Throughput Automated Electrophysiology Assay for Human Nav1.9 Inhibitor Screening

View All